XYZ Corp (XYZ) has expanded its recent stock offering to 3.07 million shares, up from the initially planned 2.33 million. This adjustment comes alongside the pricing of the shares being set below the last closing market value of $6.03. The underwriter for this offering is ThinkEquity, serving as the sole book-running manager. This strategic move may indicate the company's intent to bolster capital while aiming to attract investor interest despite the discounted rate.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for BriaCell Therapeutics Corp (BCTX, Financial) is $225.00 with a high estimate of $225.00 and a low estimate of $225.00. The average target implies an upside of 3,631.34% from the current price of $6.03. More detailed estimate data can be found on the BriaCell Therapeutics Corp (BCTX) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, BriaCell Therapeutics Corp's (BCTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
